REPLY
23.10.2018 13:02:04 CEST | Business Wire | Press release
Today Oracle awarded Business Reply with its 2018 Oracle Excellence Award for Specialized Partner of the Year – EMEA in ERPM Cloud.
The Oracle Excellence Awards for Specialized Partner of the Year – EMEA recognizes Business Reply for their outstanding work in driving customer success with ERP Cloud offering. Oracle partners accelerate innovation and customers upgrade to the cloud. From business planning and implementation, to connectivity and data center services, Oracle PartnerNetwork (OPN) members provide the support and services needed to maximize the value of Oracle Cloud solutions for customers’ organization, and it offers its members unique opportunities to accelerate and expand their business.
Business Reply is a Platinum Cloud Select level member of Oracle PartnerNetwork (OPN). Business Reply was presented the 2018 Oracle Excellence Award for Specialized Partner of the Year – EMEA in ERPM Cloud for demonstrating an outstanding and innovative solution based on Oracle products.
The Oracle Excellence Awards for Specialized Partner of the Year – EMEA encourages innovation by Oracle PartnerNetwork (OPN) members, who use Oracle’s products and technology to create value for customers and generate new business potential.
Business Reply, the Reply Group company focused on Oracle SAAS, has been able to see the advantages of the Cloud in time and it has helped European companies to grasp the potential of the cloud, giving life to ambitious ERP cloud projects able to transform the business and services in depth.
Business Reply represents a point of reference among companies for ERP and Corporate Governance services, and it guarantees a deep knowledge of business processes together with a strong technical expertise on all Oracle application solutions.
Filippo Rizzante, CTO at Reply, said, “We are absolutely delighted to have won the award for Specialized Partner of the Year: ERPM Cloud – EMEA. Continuous investments in innovation and research & development have been critical to the creation of the most innovative ERP Cloud projects on Oracle technologies. The relationship and collaboration with Oracle has been instrumental to the success of Business Reply, enabling the team to maintain innovation as the Oracle platform evolves.”
“Business Reply has demonstrated an outstanding level of innovation in delivering proven, Oracle-based ERP Cloud solutions that solve our joint customers’ most critical business challenges,” said Javier Torres, Vice President Alliances & Channels Oracle EMEA. “We congratulate Business Reply in achieving the 2018 Oracle Excellence Award for Specialized Partner of the Year – EMEA in ERPM Cloud. This achievement is a testament to their dedication to excellence and to providing customers solutions that drive real business value and results.”
About Business Reply
Business Reply, the Reply Group company specialising in the creation of integrated systems based on Oracle application suites, is Oracle Platinum Cloud Select Partner. With over 18 years of experience and more than 80 completed projects, Business Reply represents a point of reference among companies for ERP and Corporate Governance services. Strongly oriented towards Digital Transformation, thanks to investments in innovation and research & development and a process of continuous training and specialization of its resources, Business Reply was the first Italian Oracle Partner to realize projects on Oracle ERP Cloud, OTM Cloud and Service Cloud. In 2018, Business Reply has been recognized by Oracle: “Cloud Excellence Implementer”, for providing superior customer experience through successful Oracle HCM Cloud Services implementations.
About Oracle PartnerNetwork
Oracle PartnerNetwork (OPN) is Oracle's partner program that provides partners with a differentiated advantage to develop, sell and implement Oracle solutions. OPN offers resources to train and support specialized knowledge of Oracle’s products and solutions and has evolved to recognize Oracle’s growing product portfolio, partner base and business opportunity. Key to the latest enhancements to OPN is the ability for partners to be recognized and rewarded for their investment in Oracle Cloud. Partners engaging with Oracle will be able to differentiate their Oracle Cloud expertise and success with customers through the OPN Cloud program – an innovative program that complements existing OPN program levels with tiers of recognition and progressive benefits for partners working with Oracle Cloud. To find out more visit: http://www.oracle.com/partners .
Trademarks
Oracle and Java are registered trademarks of Oracle and/or its affiliates.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181023005365/en/
Contact:
Reply Fabio Zappelli f.zappelli@reply.com or Aaron Miani a.miani@reply.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom